$4.5M
2 filings since 2025 · latest SAFE filed
Neutrolis Inc. is a clinical-stage biotechnology firm that specializes in developing innovative therapies aimed at autoimmune and inflammatory diseases. The company's unique approach focuses on targeting Neutrophil Extracellular Traps (NETs), which are implicated in tissue damage and chronic inflammation associated with several immune-mediated disorders, such as lupus and dry eye disease, as well as severe complications from conditions like COVID-19.
What sets it apart
Neutrolis stands out by developing therapies that specifically target the harmful effects of NETs without broadly suppressing immune function.
The exDNASE™ platform is Neutrolis’s proprietary technology designed to engineer enzymes specifically for the degradation of Neutrophil Extracellular Traps (NETs). This platform is pivotal in developing therapies that can mitigate the damaging effects of overactive neutrophils in autoimmune and inflammatory diseases.
